IMRT Tomotherapy for Esophagus Cancer
Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Jan 2, 2008
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18
- • Karnofsky Performance Status of \>= 60
- • TNM Stages T1-4, N0-3, M0
- • Pathologic confirmation of esophagus cancer
- • Evaluation by medical oncologist determines that the patient is medically fit for concurrent chemotherapy
- • Evaluation by surgeon determines that patient is unresectable
- Exclusion Criteria:
- • Age \< 18
- • Karnofsky Performance Status \< 60
- • Radiographic or pathologic evidence of distant metastatic disease (classified as M1b in AJCC staging manual)
- • Prior radiation therapy to the thorax or upper abdomen, preventing definitive radiation therapy.
- • Pregnant or lactating, if female.
About Washington University School Of Medicine
Washington University School of Medicine is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research, education, and patient care. With a strong emphasis on translating scientific discoveries into practical applications, the institution conducts a diverse array of clinical trials aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. Its collaborative environment fosters partnerships between researchers, clinicians, and community stakeholders, ensuring that the trials not only contribute to scientific knowledge but also address the pressing health needs of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
St. Louis, Missouri, United States
Patients applied
Trial Officials
Jeffrey Bradley, MD
Principal Investigator
Washington University School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials